AI-powered cardiometabolic wellness platform for India’s workforce

Lupin Digital Health, India’s leading cardiac digital-therapeutics company, today announced the launch of VITALYFE, an AI-powered cardiometabolic wellness platform designed to help India’s working professionals reclaim their heart health. Built on the foundation of LYFE — India’s first CDSCO-approved Class C software medical device (SaMD) for critical cardiac conditions — extends hospital-grade cardiac expertise to preventive wellness for its users.

“Cardiometabolic risks silently erode both health and productivity,” said Rajeev Sibal, President – India Region Formulations, Lupin. “With VITALYFE, we are enabling insurers and employers to combine clinical expertise with AI-driven technology to deliver scalable, measurable wellness outcomes for millions of working Indians.”

Developed with industry-leading cardiometabolic expertise, VITALYFE uses artificial intelligence, behavioral science, and computer-vision technology to identify early risks and provide personalised, non-medical interventions that address the root causes of heart aging.

Available exclusively through insurers, brokers, and employers, the platform enables organizations to integrate cardiometabolic wellness into their health benefits — improving productivity, engagement, and overall well-being while helping insurers reduce lifestyle-related claims.

“At Lupin Digital Health, we have seen how evidence-based digital therapeutics through LYFE have transformed cardiac recovery,” said Sidharth Srinivasan, Chief Executive Officer – Lupin Digital Health. “With VITALYFE, we are extending that scientific foundation to a much larger audience — helping professionals understand their heart age, make better lifestyle choices, and literally make their hearts younger. Our vision is to make cardiometabolic wellness both measurable and mainstream.”